IL194628A0 - Use of escitalopram for improving cognition - Google Patents

Use of escitalopram for improving cognition

Info

Publication number
IL194628A0
IL194628A0 IL194628A IL19462808A IL194628A0 IL 194628 A0 IL194628 A0 IL 194628A0 IL 194628 A IL194628 A IL 194628A IL 19462808 A IL19462808 A IL 19462808A IL 194628 A0 IL194628 A0 IL 194628A0
Authority
IL
Israel
Prior art keywords
escitalopram
improving cognition
cognition
improving
Prior art date
Application number
IL194628A
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of IL194628A0 publication Critical patent/IL194628A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL194628A 2006-05-02 2008-10-07 Use of escitalopram for improving cognition IL194628A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200600621 2006-05-02
PCT/DK2007/050050 WO2007124757A2 (en) 2006-05-02 2007-04-30 Use of escitalopram for improving cognition

Publications (1)

Publication Number Publication Date
IL194628A0 true IL194628A0 (en) 2009-08-03

Family

ID=38134951

Family Applications (1)

Application Number Title Priority Date Filing Date
IL194628A IL194628A0 (en) 2006-05-02 2008-10-07 Use of escitalopram for improving cognition

Country Status (15)

Country Link
EP (1) EP2026793A2 (en)
JP (1) JP2009535367A (en)
KR (1) KR20090009820A (en)
CN (1) CN101426494A (en)
AR (1) AR060732A1 (en)
AU (1) AU2007245983A1 (en)
BR (1) BRPI0710230A2 (en)
CA (1) CA2651002A1 (en)
EA (1) EA200870491A1 (en)
IL (1) IL194628A0 (en)
MX (1) MX2008013911A (en)
NO (1) NO20085009L (en)
TW (1) TW200812993A (en)
WO (1) WO2007124757A2 (en)
ZA (1) ZA200808632B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4745661B2 (en) 2002-08-22 2011-08-10 大日本住友製薬株式会社 Schizophrenia treatment
AU2004249621B2 (en) 2003-06-23 2009-08-06 Dainippon Sumitomo Pharma Co., Ltd. Therapeutic agent for senile dementia
WO2005080976A1 (en) 2004-02-20 2005-09-01 Dainippon Sumitomo Pharma Co., Ltd. Method of in vivo screening of therapeutic agent for memory/learning dysfunction by schizophrenia
EA018064B1 (en) * 2007-08-03 2013-05-30 Рихтер Гедеон Нирт. Method of treating depression
EP2236138A1 (en) * 2009-03-30 2010-10-06 PharmaNeuroBoost N.V. Low dose pipamperone in treating mood and anxiety disorders
US8258139B2 (en) 2010-11-08 2012-09-04 Dainippon Sumitomo Pharma Co., Ltd. Method of treatment for mental disorders
EP3069718A1 (en) * 2015-03-17 2016-09-21 Universidade do Minho Citalopram or escitalopram for use in the treatment of neurodegenerative diseases
MX2019007389A (en) 2016-12-20 2019-08-16 Lts Lohmann Therapie Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene.
US20180193283A1 (en) 2016-12-20 2018-07-12 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
JP2020525545A (en) 2017-06-26 2020-08-27 エルテーエス ローマン テラピー−ジステーメ アーゲー Transdermal therapeutic system containing asenapine and silicone-acrylic hybrid polymer
CA3101420A1 (en) 2018-06-20 2019-12-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
KR102051624B1 (en) * 2018-11-30 2019-12-02 아밀로이드솔루션 주식회사 Pharmaceutical composition for treatment of neurodegenerative brain disease comprising triflupromazine or pharmacurically acceptable salt thereof as an active ingredient
CN109464436A (en) * 2019-01-10 2019-03-15 高智玉 Citalopram or escitalopram combine the application in the compound preparation of preparation treatment phrenoblabia class disease with Quetiapine respectively

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK213290D0 (en) * 1990-09-06 1990-09-06 Lundbeck & Co As H TREATMENT OF CEREBROVASCULAR DISORDERS
SE9803158D0 (en) * 1998-09-16 1998-09-16 Astra Ab A new composition
SE9803157D0 (en) * 1998-09-16 1998-09-16 Astra Ab A new composition
US6617361B2 (en) * 1999-11-05 2003-09-09 Be Able, Llc Behavior chemotherapy
ES2266008T3 (en) * 2000-12-01 2007-03-01 Be Able, Llc BEHAVIOR CHEMOTHERAPY.
WO2002076461A1 (en) * 2001-03-26 2002-10-03 Serdar Murat Dursun Combination of reboxetine and citalopram
CA2445843A1 (en) * 2001-05-01 2002-11-07 H. Lundbeck A/S The use of enantiomeric pure escitalopram
US20050014848A1 (en) * 2002-01-23 2005-01-20 Pfizer Inc. Combination of serotonin reuptake inhibitors and norephinephrine reuptake inhibitors
MXPA05000294A (en) * 2002-07-30 2005-08-19 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions.
PT1578738E (en) * 2002-12-23 2008-04-11 Lundbeck & Co As H Escitalopram hydrobromide and a method for the preparation thereof
AU2004269858A1 (en) * 2003-09-04 2005-03-17 H. Lundbeck A/S The combination of a serotonin reuptake inhibitor and Loxapine
EP1954257A4 (en) * 2005-10-14 2009-05-20 Lundbeck & Co As H Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
CA2626025A1 (en) * 2005-10-14 2007-04-26 Forest Laboratories, Inc. Stable pharmaceutical formulations containing escitalopram and bupropion
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram

Also Published As

Publication number Publication date
TW200812993A (en) 2008-03-16
AR060732A1 (en) 2008-07-10
CN101426494A (en) 2009-05-06
AU2007245983A1 (en) 2007-11-08
KR20090009820A (en) 2009-01-23
BRPI0710230A2 (en) 2011-08-02
WO2007124757A3 (en) 2008-07-24
MX2008013911A (en) 2008-11-12
JP2009535367A (en) 2009-10-01
NO20085009L (en) 2008-12-16
CA2651002A1 (en) 2007-11-08
ZA200808632B (en) 2009-12-30
EA200870491A1 (en) 2009-04-28
WO2007124757A2 (en) 2007-11-08
EP2026793A2 (en) 2009-02-25

Similar Documents

Publication Publication Date Title
ZA200808632B (en) Use of escitalopram for improving cognition
EP2068864A4 (en) Therapeutic uses of urolithins
IL202664A (en) Processes for the preparation of 3-dihalomethyl-1-methyl-1h- pyrazole-4-carbaldehyde and intermediates
ZA200900886B (en) Use of azabicyclo hexane derivatives
AU311449S (en) Ncs-emg instrument
IL197632A0 (en) Use of jam-c binding compounds
IL196606A0 (en) Use of escin
GB0705854D0 (en) Methods of construction
IL197966A0 (en) Use of modified cyclosporin
TWI320362B (en) Enhanced imaging of features
EP1931370A4 (en) Use of des-aspartate-angiotensin i
GB0700179D0 (en) Use of epoxidised compounds
SI2038260T1 (en) Stereoselective synthesis of (s)-1-methyl-3-phenylpiperazine
HU0500947D0 (en) Composition for treatment of paradontosis
PL381142A1 (en) The manner of obtaining of glicydol
GB0624439D0 (en) Technique for treatment of gall-and kidney-stones
GB0602857D0 (en) The treatment of sialorrhoea
HUP0500948A2 (en) Composition for treatment of diabeticus paradontosis
GB0612370D0 (en) Uses of (S)-clenbuterol
GB0604575D0 (en) Construction of inductive components
PL1886669T3 (en) Phosphoglucan based immunotrophic preparation for the treatment of adenotonsillar hypertrophy
GB2443891B (en) Process for the purification of meloxicam
GB0625602D0 (en) Treatment of sialorrhoea
IL198836A0 (en) Processes for preparation of 9-haloacetamidomidominocyclines
GB0602858D0 (en) The treatment of sialorrhoea